Shares expected to begin trading on split-adjusted basis on July 18, 2024SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”) , a ...

Senti Biosciences, Inc. (NASDAQ:SNTI) stock is skyrocketing on Monday, with a strong session volume of 73.4 million compared to an average volume of 17.81 thousand, as per data from Benzinga Pro.

Senti Biosciences (SNTI) stock soared 175% in after-hours trading after it announced a collaboration with Celest Therapeutics to develop its drug SENTI-301A for the Chinese market.

(RTTNews) - Senti Biosciences, Inc. (SNTI), a clinical-stage biotechnology company, on Monday announced an additional $11.5 million in funding, including a $10 million investment from Celadon ...

SENTI-301A is an off-the-shelf CAR-natural killer cell therapy for GPC3 expressing tumors derived from healthy donor cells. The therapy was shown in preclinical testing to kill relevant tumor cells.

Lots of work stands between Senti and the realization of that vision but it has persuaded some major investors to back its plans. NEA led the A round with the support of 8VC, Amgen Ventures, Pear ...